Alzheimer disease trials in Italy

In Italy 60 Also abroad 815

60 trials · From ClinicalTrials.gov and EU CTIS (euclinicaltrials.eu), checked 11 November 2026. Ask the study team whether a trial fits you.

Phase 2/3Taking people
A Study of Treatments for the Prevention of Disease Progression in Individuals at Risk for or With Early Onset Alzheimer’s Disease Caused by a Genetic Mutation
Where
Brescia, Florence
Age
18 years and over
People
27 worldwide
Run by
Washington University School Of Medicine
See details and how to join2024-517187-36-01 · EU 2024-517187-36-01
No phaseNot yet taking people in Italy
Using Artificial Intelligence to Detect Early Signs of Alzheimer's Disease in People With Memory Concerns
Where
Milan
Age
40 years and over
People
300
Run by
IRCCS San Raffaele
See details and how to joinNCT07652931
No phaseTaking people
InRAD Observational Study
Where
Foggia, Milan
Age
18 years and over
People
50,000 worldwide
Run by
Stichting International Registry for Alzheimer's Disease and other Dementias Foundation
See details and how to joinNCT07213700
Phase 2/3Taking people
Safety and Efficacy of EXV-802 and EXV-801 in the Treatment of Agitation in Alzheimer's Disease Dementia
Where
Brescia, Chieti Scalo, Milan, Palermo, Rome, Tricase
Age
55 years to 90 years
People
300 worldwide
Run by
Exciva GmbH
See details and how to joinNCT07284472 · EU 2024-517388-22-00
Phase 2Taking people
Study to Test Effects and Safety of RO7568282 in Early Symptomatic Alzheimer's Disease
Where
Brescia, Cefalu', Milan, Rome
Age
50 years to 90 years
People
450 worldwide
Run by
Hoffmann-La Roche
See details and how to joinNCT07781657 · EU 2026-526158-14-00
Phase 2/3Taking people
ACP-204 in Adults With Alzheimer's Disease Psychosis
Where
Brescia, Cefalu', Milan, Pozzilli, Rome, Salerno, Tricase, Turin
Age
55 years to 95 years
People
1,074 worldwide
Run by
ACADIA Pharmaceuticals Inc.
See details and how to joinNCT06159673 · EU 2023-507325-42-00
No phaseTaking people
Transcranial Alternating Current Stimulation (tACS) Combined With Cognitive Training in Alzheimer's Disease
Where
Brescia, Milan
Age
18 years and over
People
30
Run by
IRCCS Centro San Giovanni di Dio Fatebenefratelli
See details and how to joinNCT07839650
Phase 3Enrolling by invitation
ACP-204 in Adults With Alzheimer's Disease Psychosis Open Label Extension Study
Where
Brescia, Cefalu', Milan, Pozzilli, Rome, Salerno, Tricase, Turin
Age
55 years to 95 years
People
752 worldwide
Run by
ACADIA Pharmaceuticals Inc.
See details and how to joinNCT06194799 · EU 2023-507351-29-00
Phase 2Taking people
A Study to Assess the Efficacy and Safety of ITI-1284 in the Treatment of Psychosis Associated With Alzheimer's Disease
Where
Arzignano, Brescia, Cefalù, Tricase
Age
55 years and over
People
370 worldwide
Run by
Intra-Cellular Therapies, Inc.
See details and how to joinNCT06540833
Phase 3Taking people
A Phase 3 Study to Evaluate the Safety and Efficacy of KarXT + KarX-EC for the Treatment of Agitation Associated With Alzheimer's Disease
Where
Brescia, Milan, Naples, Pisa, Rome
Age
55 years to 90 years
People
426 worldwide
Run by
Bristol-Myers Squibb
See details and how to joinNCT07011745 · EU 2025-520612-34-00
No phaseTaking people
Motor Learning in Health and Movement Disorders: Role of Physical Activity and Advanced Devices
Where
Messina
Age
18 years to 70 years
People
150
Run by
IRCCS Centro Neurolesi Bonino Pulejo
See details and how to joinNCT07066137
No phaseTaking people
Automated Language Analysis in Neurodegenerative Diseases: Application of Artificial Intelligence Models
Where
Bari
Age
40 years to 90 years
People
200
Run by
Istituti Clinici Scientifici Maugeri SpA
See details and how to joinNCT07906769
No phaseTaking people
Development, Validation and Normative Data of the Italian Battery for the Recognition of Famous Faces (FAME)
Where
Bari, Castel Goffredo, Lumezzane, Milan, Mistretta, Montescano, Pavia, Sciacca, Telese Terme, Veruno
Age
40 years to 85 years
People
300
Run by
Istituti Clinici Scientifici Maugeri SpA
See details and how to joinNCT07911878
Phase 3Taking people
A Study to Evaluate KarXT as a Treatment for Psychosis Associated With Alzheimer's Disease (ADEPT-4)
Where
Brescia, Milan, Rome
Age
55 years to 90 years
People
406 worldwide
Run by
Karuna Therapeutics, Inc., a Bristol Myers Squibb company
See details and how to joinNCT06585787 · EU 2024-516363-92-00
Phase 3Taking people
A Study to Evaluate the Efficacy and Safety of KarXT + KarX-EC for Cognitive Impairment in Alzheimer's Disease
Where
Brescia, Milan, Monza
Age
60 years to 85 years
People
586 worldwide
Run by
Bristol-Myers Squibb
See details and how to joinNCT06976216 · EU 2025-520746-30-00
No phaseTaking people
Speech and Language Interventions for Italian People With PPA
Where
Bari, Milan
Age
40 years to 85 years
People
30
Run by
Istituti Clinici Scientifici Maugeri SpA
See details and how to joinNCT06739967
Phase 3Taking people
Screening Study to Determine Individuals With Potential Trial Eligibility for Alzheimer's Disease Studies
Where
Brescia, Genoa, Milan, Naples, Palermo, Perugia, Rome
Age
50 years to 90 years
People
80,000 worldwide
Run by
Hoffmann-La Roche
See details and how to joinNCT07177352
Phase 3Taking people
Open-Label Extension Study to Assess the Long-Term Safety and Tolerability of KarXT in Subjects With Psychosis Associated With Alzheimer's Disease (ADEPT-3)
Where
Brescia, Milan, Modena, Ponderano, Roma, Rome, Salerno
Age
55 years to 90 years
People
1,000 worldwide
Run by
Karuna Therapeutics, Inc., a Bristol Myers Squibb company
See details and how to joinNCT05980949 · EU 2023-504151-27-00
Phase 3Taking people
A Study to Evaluate the Long-term Efficacy and Safety of KarXT + KarX-EC for Agitation in Alzheimer's Disease (ADAGIO-3)
Where
Brescia, Milan, Naples, Pisa, Rome
Age
55 years to 90 years
People
650 worldwide
Run by
Bristol-Myers Squibb
See details and how to joinNCT06937229 · EU 2024-519994-20-00
Phase 2Taking people
A Study to Evaluate Mivelsiran in Adult Participants With Early-Stage Down Syndrome-Associated Alzheimer's Disease (DS-AD)
Where
Rome
Age
40 years to 55 years
People
58 worldwide
Run by
Alnylam Pharmaceuticals
See details and how to joinNCT07636811 · EU 2025-523390-42-00
Phase 3Taking people
A Study to Evaluate the Efficacy and Safety of KarXT + KarX-EC for Cognitive Impairment in Alzheimer's Disease (MINDSET 2)
Where
Foggia, Naples, Rome
Age
60 years to 85 years
People
586 worldwide
Run by
Bristol-Myers Squibb
See details and how to joinNCT06976203 · EU 2025-520747-32-00
No phaseTaking people
Restoring Cervical Lymphatic Drainage in Alzheimer's Disease
Where
Siena
People
5
Run by
University of Siena
See details and how to joinNCT07854327
Phase 2Taking people
A Study to Assess the Efficacy and Safety of ML-007C-MA for the Treatment of Alzheimer's Disease Psychosis
Where
Rome, Tricase
Age
55 years to 90 years
People
300 worldwide
Run by
MapLight Therapeutics
See details and how to joinNCT06887192 · EU 2024-519820-26-00
No phaseTaking people
Longitudinal Profiling of Plasma-Derived Glial Extracellular Vesicles in Alzheimer's Disease
Where
Rome
Age
55 years to 80 years
People
48
Run by
Fondazione Policlinico Universitario Agostino Gemelli IRCCS
See details and how to joinNCT07803055
No phaseTaking people
Autonomic Involvement in Patient With Cognitive Decline
Where
Rome
Age
50 years to 85 years
People
120
Run by
Fondazione Policlinico Universitario Agostino Gemelli IRCCS
See details and how to joinNCT06292741